Sensitivity analyses confirmed the robustness, and no significant publication bias was detected.<h4>Conclusions</h4>ctDNA clearance during EGFR-TKI treatment appears to be associated with improved survival outcomes in patients with EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.